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Abstract: The MYC transcription factor is one of the best characterized PP2A substrates. Deregulation
of the MYC oncogene, along with inactivation of PP2A, are two frequent events in cancer. Both
proteins are essential regulators of cell proliferation, apoptosis, and differentiation, and they, directly
and indirectly, regulate each other’s activity. Studies in cancer suggest that targeting the MYC/PP2A
network is an achievable strategy for the clinic. Here, we focus on and discuss the role of MYC and
PP2A in myeloid leukemias.
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1. Introduction
Myeloid cells, including erythrocytes, monocytes/macrophages, granulocytes, and megakaryocyte/
platelets and dendritic cells, are key effector cells of the innate immune defense against invading
micro-organisms [1]. These cells are continuously generated from hematopoietic stem cells in the
bone marrow through a well-timed and regulated process named myelopoiesis [2]. Deregulation of
proliferation and lineage differentiation due to the genetic and epigenetic aberrations is linked to blood
cell disorders such as acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) [3].
Research in hematology has fundamentally improved our understanding of the biology of cancer
and resulted in many innovative discoveries [4]. Many genetic aberrations have prognostic impact on
myeloid leukemias, including the overexpression of the MYC, CIP2A, and SET oncogenes. MYC is
a master transcription factor that regulates a wide spectrum of target genes, and is found altered in
several types of cancer [5,6]. CIP2A and SET are endogenous inhibitors of the phosphatase 2A (PP2A),
a tumor suppressor protein that is recurrently inactivated in acute and chronic myeloid leukemias [7].
PP2A is a key regulator of many oncoprotein signaling pathways involved in the regulation of cell
growth and survival, including MYC. Mainly, PP2A activity leads to MYC degradation [8]; therefore,
its role in regulating MYC biology is fundamental to maintain a correct balance between normal and
aberrant phenotype. In this review, we focus on the role of MYC and PP2A in the myeloid leukemia
initiation and progression.
1.1. Acute Myeloid Leukemia (AML)
AML is a clonal malignancy that results from genetic and epigenetic abnormalities which leads
to uncontrolled proliferation and impaired differentiation of hematopoietic stem and progenitor
cells [9–11]. Cytogenetic analysis for the detection of chromosomal abnormalities was the first
prognostication tool in AML and still remains the backbone of current AML genomic classification [12].
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With the advancement of genetic and next-generation sequencing approaches, recurrent mutations in
AML have also been characterized [13,14]. The genetic profile of AML is notably heterogeneous, and
only a few mutations (i.e., FLT3, NPM1, and DNMT3A) are present in more than a quarter of AML
patients [15]. Transcription factors are a class of genes that are frequently altered in AML, such as
PML, EVI1, GATA2, RUNX1, ETV6, and C/EBPα, which establish and maintain genetic networks
governing the genesis and function of blood stem and progenitor cells [16]. Furthermore, a recent
genomic analysis in over 1500 AML patients identified novel hotspot mutations in another critical
transcription factor, such as MYC [17]. MYC high expression is also common in AML.
Scientific understanding of the AML biology has led to the development of targeted treatment
approaches [4], i.e., the all-trans retinoic acid (ATRA) treatment for acute promyelocytic leukemia (APL)
that carries the PML-RARα translocation [18] or the use of FLT3 kinase inhibitors in FLT3-mutated
cases [19,20]. Nevertheless, the treatment of AML has been mostly unmodified for the past decades.
Although many patients with AML respond to induction chemotherapy, relapse is common and
represents the primary cause of treatment failure [9]. Interestingly, bone marrow environment has
been suggested to play a role in this unresponsive phenotype, by providing shelter to leukemic stem
cells, whose persistence eventually leads to therapy resistance [21].
1.2. Chronic Myeloid Leukemia (CML)
CML is a type of leukemia with an initial chronic phase (CP) characterized by a massive expansion
of myeloid precursors and mature cells, followed by a late acute phase termed “blast crisis” (BC), which
resembles AML [22]. CML biology is characterized by the presence of the reciprocal translocation
t(9;22)(q34;q11) that generates a BCR-ABL fusion protein with aberrant and uncontrolled activity [23].
The development of a BCR/ABL kinase inhibitor, imatinib, was a significant major improvement in
CML treatment [24]. However, imatinib, and second and third-generation tyrosine kinase inhibitors’
effectiveness is often inadequate as resistant CML stem cells and residual disease persist in many
patients [25–27]. Genomic sequencing of CML patients has identified additional genetic changes,
like mutations of the tumor suppressor genes RB1, TP53, and CDKN2A [28], and highlighted the
fact that BCR-ABL kinase mutations are only identified in approximately 50% of patients with poor
responses and disease progression [29]. Therefore, progress in our understanding of CML biology is
still required.
1.3. MYC
MYC is a master transcription factor of the helix-loop-helix leucine zipper (HLHZ) family [30].
MYC forms an heterodimer with MAX and binds to E-box sequences in the regulatory regions of
numerous target genes [31] involved in the control of proliferation and differentiation, metabolism,
cell growth, among other processes [32,33]. The expression of MYC is tightly controlled in normal cells.
However, the aberrant activity of MYC is one of the most common events in solid and hematopoietic
neoplasias [31].
The MYC gene was first discovered as the oncogene carried by a retrovirus that induced a myeloid
neoplasm in chicken, i.e., myelocytomatosis [34] and a few years later identified in human Burkitt
lymphoma and in mouse plasmacytomas [35,36]. MYC is amplified or deregulated in both AML and
CML; however, the mechanisms that lead to MYC overexpression in AML are still not well-defined.
It has been suggested that the aberrant activity of rearranged transcription factors (i.e., RUNX1-ETO,
PML-RARα, and PLZF-RARα) might increase MYC expression. Trisomy 8, where MYC is localized,
could represent another potential mechanism. MYC upregulation is usually moderate in myeloid
leukemias, yet, enough to generate radical changes in the myeloid precursor differentiation [37].
MYC is a short half-live protein; thus, its post-transcriptional regulation plays an essential role in
its stability and function. Two interdependent phosphorylation sites that are critical for the regulation
of MYC have been identified. Activation of the ERK cascade or cyclin-dependent kinases (CDKs)
leads to the phosphorylation of MYC at Serine 62 (S62) [38]. This modification enhances MYC DNA
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binding and gene regulation. Phosphorylation of S62 also primes MYC for glycogen synthase kinase
3 (GSK3)-mediated phosphorylation at Threonine 58 (T58) [39], which initiates MYC turnover [8].
Dual phosphorylated MYC (S62 and T58) becomes target of the PP2A, which dephosphorylates the
stabilizing S62 residue and marks MYC for ubiquitin-mediated proteosomal degradation [40] (Figure 1).
Figure 1. MYC regulation by PP2A. MYC undergoes two critical phospho-modifications on S62 and
T58 residues. The phosphorylation on T58 is regulated by GSK3β. To be active, GSK3β has to be
dephosphorylated. The PP2A complex, which includes the B56α subunit, dephosphorylates and
activates GSK3β. Interestingly, the B56α subunit is transcriptionally activated by MYC. Moreover,
the presence of a phosphorylated T58 residue also recruits the PP2A-B56α complex, which
dephosphorylated the S62 phospho-residue. Dephosphorylation of S62 residue eventually targets MYC
for ubiquitin-mediated proteosomal degradation. See text for more details.
1.4. MYC in Myeloid Leukemias
The mechanisms behind MYC-driven oncogenesis in AML are still underexplored. Different
murine models, either using engraftment of hematopoietic precursors over-expressing MYC or
transgenic mice, demonstrated the myeloid leukemogenic activity of MYC [37] and highlighted the
significance of MYC-driven abrogation of apoptosis as key molecular mechanism [41,42]. In APL, MYC
cooperates with PML-RARα to accelerate the development of leukemia [43], while in AML, MYC protein
expression is a poor prognostic factor, particularly in patients with high risk of relapse [44,45]. It has been
reported that the inhibition of MYC in AML cell lines drastically induces cell differentiation [46], and
studies in mice have demonstrated that even transient inactivation of MYC yields tumor regression [47],
supporting the hypothesis that targeting MYC regulation could be a highly pursued goal to treat
cancer patients.
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In CML, it has been widely reported that the BCR-ABL aberrant kinase activity induces MYC
transcription [48] and translation, and that the progress into blast crisis depends on this BCR-ABL-
induced MYC expression [49]. The generation of a mouse model with an inducible BCR-ABL along
with sequentially and spontaneously activated mutations, helped to recapitulate the human CML
biology. Interestingly, Giotopoulos et al. identified potentially targetable pathways in CML such
as ERG, MEK, RAF, JAK1/2, and confirmed that MYC is crucial for CML-progression to BC [50].
Additionally, MYC and its partner MAX bind to the BCR promoter, enhancing BCR-ABL mRNA and
protein content, creating a feedback loop that is key for CML transition to BC [51]. Nevertheless, Reavie
et al. recently showed that MYC is essential but not sufficient for CML induction and progression.
Additional mutations, such as p53 loss, are needed to sustain CML pathobiology [52].
Yet, high levels of MYC correlate with poor response to imatinib and, at molecular level, MYC
induces genomic instability [53]. Also, MYC’s negative regulation of p27kip1 protein stability seems to
be critical. By inducing SKP2, a component of the ubiquitin ligase complex that targets p27kip1 for
degradation, MYC prevents cell differentiation [54].
1.5. PP2A
Reversible phosphorylation is one of the mechanisms that cells use to maintain normal
homeostasis [7], yet the role of phosphatases in cancer has just started to be fully considered. PP2A is
a serine-threonine phosphatase that dephosphorylates serines or threonines residues of key factors
involved in the regulation of cell proliferation, survival, and differentiation and that together with PP1,
contributes >90% of the phosphatase activity of the cell [55]. Such wide-ranging substrate specificity
is achieved by the formation of at least 100 distinct heterotrimeric holoenzymes, each containing
a common core enzyme formed by the catalytic (C) and scaffold (A) subunits and a third variable
regulatory subunit (B) that determine substrate specificity and subcellular localization [56]. In humans,
the C and A subunits are each encoded by two different genes, giving rise to two isoforms of the C
subunit (PPP2CA and PPP2CB), and A subunit (PPP2R1A and PPP2R1B). For the B-type subunits,
15 human genes have been described, giving rise to more than 23 isoforms belonging to four different
families, PR55 ⁄ B (or B55, encoded by PPP2R2A to PPP2R2D), PR61 ⁄ B’ (or B56, encoded by PPP2R5A
to PPP2R5E), PR72 ⁄ B” (encoded by PPP2R3A to PPP2R3C), and PR93 ⁄ PR110 ⁄ B”’ (or the striatins,
encoded by STRN, STRN3 and STRN4) (Table 1). This diversity in composition creates specificity and
forms the basis for PP2A’s multiple physiological functions [57,58]. Particularly, complexes containing
PP2A B56α, B56γ, B55α, and PR72/PR130 have been reported to specifically activate MYC, WNT, ERK
MAPK, and PI3K/AKT pathways and, thus, considered actionable targets [56,59–61].
Cells 2020, 9, 544 5 of 16
Table 1. PP2A subunits and reported alterations in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
Subunit. Gene Locus Protein Alteration in AML Alteration in CML
A Structural PPP2R1A 19q13.41 PR65/Aα Downregulation [62].Oncogenic c-KIT mutations decrease protein levels [63].
Increased levels in
BCR/ABL cells [64].
PPP2R1B 11q23.1 PR65/Aβ Downregulation [65]
C Catalytic PPP2CA 5q31.1 PP2A-C/C α
Downregulation in TP53 mutant AML cases [65].
Decreased expression in del5q AML [66]. Gene deletion
in pediatric AML [67].
Hyperphosphorylation of Y307 [68].
Hyperphosphorylation of
Y307 and T304 [64].
PPP2CB 8p12 PP2A-C/C β
B Regulatory PPP2R2A 8p21.2 PR55/B55 α Oncogenic c-KIT mutations decrease protein levels [63].Downregulation at mRNA and protein level [62,69,70].
PPP2R2B 5q32 PR55/B55 β High expression [65].
PPP2R2C 4p16.1 PR55/B55 γ Downregulation [65].
PPP2R2D 10q26.3 PR55/B55 δ
B’ Regulatory PPP2R5A 1q32.3 PR56/B56 α Oncogenic c-KIT mutations decrease protein levels [63].Gene amplification in pediatric AML [67].
PPP2R5B 11q13.1 PR56/B56 β
Downregulation [68].
High expression [65].
Gene deletion in pediatric AML [67].
PPP2R5C 14q32.31 PR56/B56 γ
Downregulation [68].
Oncogenic c-KIT mutations decrease protein levels [63].
Gene deletion in pediatric AML [67].
Decreased expression in
CML-BC compared to de
novo CML [71].
PPP2R5D 6p21.1 PR55/B55 δ Oncogenic c-KIT mutations decrease protein levels [63]
PPP2R5E 14q32.2 PR55/B55 ε Downregulation [72].
B” Regulatory PPP2R3A 3q22.2 PR72/PR130 or B” α
PPP2R3B Yp11.32;Xp22.33 PR48/PR70 or B” β Downregulation [65].
PPP2R3C 14q13.2 B” γor G5PR
B”’ Regulatory STRN 2p22.2 Striatin
STRN3 14q13-q12 Striatin3
STRN4 19q13.2 Striatin4
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PP2A is frequently inactivated in both AML and CML [64,68], and several studies now recognize
PP2A inactivation as an essential requirement for transforming human cells [56]. Mutations, mostly
in the A subunit that impair the phosphatase function or assembly, have been reported in solid
tumors. However, their incidence in myeloid leukemia is low, except for the PP2A-C subunit
haploinsufficiency in AML with deletions of chromosome 5, a region that includes other tumor
suppressor genes [65]. Altered expression of PP2A subunits is a recurrent event in AML. Mainly,
PP2A-B55α is under-expressed in primary blast cells and correlates with increased AKT phosphorylation
and shorter complete remission [7,69]. At protein level, B55α content also associates with increased
MYC activity [70]. Nevertheless, current evidence suggests that the inhibition of PP2A is mostly
achieved through non-genomic mechanisms, such as post-translational modifications of its subunits
and/or overexpression of PP2A endogenous inhibitors [7].
The activity and localization of PP2A can be regulated by post-translational modifications [73].
Methylation and phosphorylation of residues from PP2A-C subunits modulate the formation of the
complex. For instance, methylation of leucine 309 (L309) in the catalytic PP2A-C by the leucine carboxyl
methyltransferase 1 (LCMT1) [74] is required for binding of the PR55/B55 subunit [75]. Phosphorylation
of tyrosine 307 (Y307) considerably impairs PP2A phosphatase activity by inhibiting the interaction of
PP2A-C with the PTPA-activating protein, which enables the assembly of the holoenzyme [58,76], and
the regulatory subunits PR55/B55 and PR61/B56 [77]. Actually, increased phosphorylation of Y307 of
PP2A-C inversely correlates with disease prognosis in AML and CML [68,78]. In contrast, threonine
304 (T304) phosphorylation prevents the assembly of PR55/B55 to the core enzyme [75].
In AML, our group and others showed that the hyperphosphorylation of PP2A-C and consequent
inactivation is observed in 78% of AML patients, along with high levels of PP2A endogenous inhibitors
SET and CIP2A [68,79–81]. In c-KIT-mutated AML, oncogenic receptor tyrosine kinase c-KIT, which
activates proliferation, differentiation, and survival signaling pathways, requires PP2A inactivation for
leukemogenesis. Roberts et al. have shown that myeloid precursor cells expressing oncogenic mutant
c-KIT receptors display significantly reduced PP2A activity compared to c-KIT negative or wild type
c-KIT. Furthermore, inhibition of PP2A by mutant c-KIT is associated with reduced protein expression
of PP2A subunits, together with altered expression of PP2A endogenous inhibitor SET oncogene [63].
PP2A inhibitors are described in more detail in the next paragraph.
In CML, functional inactivation of PP2A by BCR-ABL is essential for the progression into blast
crisis. One suggested mechanism of inactivation is the increased expression of the PP2A-Aα subunit
observed in BCR-ABL+ cells, as the Aα subunit could sequester the catalytic or regulatory subunits and
act as a PP2A inhibitor [82]. However, it is generally believed that BCR-ABL enhances the expression
of the endogenous PP2A inhibitor SET with subsequent loss of PP2A activity [64,83]. Imatinib-derived
inhibition of BCR-ABL dramatically reduces SET expression and restores PP2A activity, resulting in
the dephosphorylation of STAT5, ERK1/2, AKT, BAD, and JAK2, substrates of both BCR-ABL and
PP2A [78,84].
1.6. PP2A Endogenous Inhibitors
Recent reports have highlighted the role of the PP2A endogenous inhibitors ANP32A, SET, CIP2A,
and ARPP19 (Figure 2), and their role in cancer progression [85,86]. Particularly, their alterations in
myeloid leukemia are reported in Table 2.
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Figure 2. MYC/PP2A inhibitory network. MYC transcriptionally regulates SET and CIP2A. SET binds
to the PP2A-C subunit, while CIP2A interacts with PP2A-B56α subunit. Their increased expressions
lead to PP2A inhibition in leukemia cells. SETBP1 is a SET binding protein overexpressed in myeloid
leukemias that prevents SET cleavage. ARPP19 is another inhibitor of PP2A that has been recently
reported to enhance the levels of CIP2A, SET, and MYC in AML.
Table 2. PP2A endogenous inhibitors and reported alterations in AML and CML.
Inhibitor Mechanism MYC Association Alteration in AML Alteration in CML
ANP32A Binds to and inactivatesPP2A-C [87,88].
High expression in
primary AML cells
[89].
SET Binds to and inactivatesPP2A-C [90].
MYC regulates SET
transcriptional
expression [91].
High expression
[68,80].
High expression [64].
Associate with
monosomy 7 and
predict worse overall
survival and
progression-free
survival [92].
CIP2A
Binds to PP2A A, B56
subunits, preventing the
dephosphorylation of
MYC [93,94]
CIP2A prevents
PP2A-dependent
dephosphorylation of
MYC on S62 [93].
MYC regulates CIP2A
expression [95].
High expression
[81,96]. High expression [97].
ARPP19 Binds and inhibits B55αδin mitosis [98,99]
ARPP19 promotes
MYC expression [100]
High expression
[100]
Cells 2020, 9, 544 8 of 16
ANP32A, (acidic nuclear phosphoprotein 32a), also known as I1PP2A (Inhibitor 1 of PP2A), is a
potent inhibitor of PP2A catalytic subunit [87,88]. It is overexpressed in primary AML cells [89] and is
a critical factor that contributes to acute megakaryoblastic leukemia progression [101].
SET, also known as Inhibitor 2 of PP2A (I2PP2A) or TAF-1 or PHAPII, is a multitask protein [102]
that along with being a histone chaperone [103] and inhibitor of histone acetylation [104] binds directly
to the catalytic subunit C of PP2A, impairing its activity [90,91]. This oncoprotein is overexpressed in
both solid and hematological tumors [64,79]. In AML, SET is highly dependent on MYC-transcriptional
activity and recruitment of RUNX1 and GATA2 on its promoter [102]. By impairing SET binding
to PP2A, with molecules like FTY720 [82,105], CM-1231 [106], or OP449 [107,108] it is possible to
re-establish PP2A activity, inhibiting tumor growth [91,109] and overcoming therapeutic resistance
in preclinical models [92,108]. SET is known to interact with SETBP1 (SET-binding protein 1), which
protects SET from protease cleavage. SETBP1 is also overexpressed in over 27% AML patients,
and its high expression significantly correlates with shorter overall survival, mostly in patients over
60 years [79]. Mutations in the SETBP1 gene have been found, and the coexistence of SETBP1 and ASXL1
mutations is known to promote leukemogenesis by repressing TGFβ pathway genes [110]. Genetic
mutations in the SETBP1 gene have also been found in CML and other myeloproliferative disorders
with no BCR-ABL translocation [111,112]. Along with its SET stabilizing function, SETBP1 additionally
promotes self-renewal of myeloid progenitors in vivo, wherein BCR-ABL positive conditions help
generating aggressive leukemias in recipient mice [113]. In addition, our group has recently shown
that p38β potentiates the inactivation of PP2A mediated by SET by two mechanisms: facilitating
cytoplasmic translocation of SET through phosphorylation of CK2, and directly binding and stabilizing
the SET protein [114].
CIP2A, also named KIAA1524, is a scaffold protein that stabilizes MYC by inhibiting the
PP2A-regulated de-phosphorylation on the residue S62 [93]. Structure analysis of the CIP2A-PP2A
interaction revealed that CIP2A forms homodimers. The dimer is stabilized by its interaction with the
PP2A-B56α and B56γ subunits [94]. CIP2A specifically interacts with PP2A-B56α holoenzyme, which
is the most ubiquitously expressed isoform of the B56 family [115] and the one that associates
with MYC to negatively regulate its protein levels and activity [38]. Thus, in the absence of
PP2A-B56α-mediated control, MYC can be aberrantly expressed. By preventing PP2A-B56α interaction
with MYC, CIP2A gained scientific attention, and it is now considered a promising target for tumor
treatment, particularly in AML [81,96,116], where it is overexpressed and promotes cell growth and
neoplastic transformation [81]. Additionally, CIP2A has been reported to be a translocation partner
with the mixed-lineage leukemia (MLL) gene [117]. In CML, CIP2A is also biologically and clinically
important [96,118], as high levels correlate not only with increased levels of MYC, but with upregulation
of the antiapoptotic protein BCL-XL [97], another important target of PP2A [119]. Additionally, CIP2A
mRNA and protein content is regulated by MYC, creating a positive feedback loop between the two
oncogenes in cancer [95]. By inhibiting MYC, by treating the cells with an inhibitor of MYC interaction
with its partner MAX through the basic-helix-loop-helix-leucine zipper domain, 10058-F4 [120], Lucas
et al. demonstrated that the levels of CIP2A and SET could be dramatically reduced, confirming once
again that studying the inhibition of MYC is worth it [121].
Among the other PP2A negative regulators, ARPP19, together with ENSA and BOD1, associates
with and inhibits PP2A to promote mitotic entry [98,122,123]. While its role in tumor progression is still
underexplored, a recent study revealed that ARPP19 mRNA expression is an independent predictor for
relapse in AML, and it might promote cell survival by regulating CIP2A and MYC expression [100].
1.7. Targeting the MYC/PP2A Axis in Leukemia
MYC is a desirable therapeutic target for several types of cancer. Yet, because of the absence
of a clear ligand-binding domain and its unstructured nature, direct targeting of MYC is still a
challenge [124,125].
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Several molecules have been described as MYC inhibitors, although none of them are used
in the clinic. The 10058-F4, which prevents the interaction of MYC with MAX, used in several
preclinical studies, was able to reduce BCR-ABL kinase activity and CIP2A expression in CML
patients [121]. In AML cells, it was reported that 10058-F4 inhibits growth, induces cell cycle arrest,
and differentiation [126]. Besides, our group described that 10058-F4 treatment also reduces SET
mRNA transcription, leading to PP2A re-establishment in AML cells [102].
Another indirect inhibitor of MYC is JQ1, a powerful inhibitor of BET bromodomain protein BRD4
which regulates MYC transcription [127]. The treatment with JQ1 or other BET inhibitors triggers
MYC downregulation with consequent cell cycle arrest and apoptosis in mouse and human leukemia
cells [128–131]. Some BET inhibitors are currently in early phase clinical trials for treating hematopoietic
malignancies and solid tumors with exciting results [132]. However, toxic side effects [133] and cases
of resistance have been reported [134].
Therefore, pointing at PP2A activation to circumvent MYC undruggability and target MYC protein
stability is considered today a suitable and attractive approach. Even though the levels of MYC after
PP2A activation have not been clearly defined in myeloid leukemias, it is known that the levels of
PP2A activity indirectly correlate with the ones of MYC.
PP2A-activating drugs are known to be highly effective in reducing MYC activity in several types
of cancers [135–137]. Notably, small molecules that prevent SET-PP2A interaction such as FTY720,
OP449, and CM-1231 re-activates PP2A, inhibiting cell proliferation and promoting apoptosis in AML
and CML cell lines and primary patient samples [62,63,68,83,92,106,108,138–140]. Combination of
FTY720 or OP449 along with Idarubicin and Ara-C, drugs used in standard induction therapy in
AML, or FLT3 inhibitors, as well as with tyrosine kinase inhibitors in CML, have a synergic effect and
significantly reduced growth of leukemic cells [92,108,138,141].
2. Conclusions
Deregulation of the MYC oncogene, along with the inactivation of PP2A, is persistently found in
myeloid leukemias, inducing tumor progression and conferring poor prognosis. Both proteins play
pivotal roles in the initiation and development of the disease and constitute attractive therapeutic
targets. As for other transcription factors, the development of molecules inhibiting MYC activity
continues to be challenging. Thus, indirect approaches have been suggested. The discovery of the
MYC/PP2A axis has set the foundation for the use of PP2A activating molecules to impair MYC stability.
Ultimately, more knowledge of the MYC/PP2A biology is needed. Nonetheless, studies in leukemia
cells and preclinical models hint that therapies targeting MYC/PP2A inhibitory network are a clinically
feasible strategy for leukemia treatment.
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